Anthony Moorman, PhD from Newcastle University, Newcastle, UK provides highlights from the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA. Dr Moorman provides detail on a paper presented by a German study group, which used whole-genome sequencing (WGS) to identify genomic lesions in acute lymphoblastic leukemia (ALL) patients. What made this trial unique was its focus on high-risk patients who had relapsed following allogeneic stem-cell transplantation. From this trial, the group were able to identify patients with targetable mutations who could benefit from treatments that are already available. This technique of characterizing high-risk disease could greatly benefit patients with high-risk ALL. This video has been supported by Incyte through an unrestricted educational grant.